Ipilimumab

Generic Name: Ipilimumab

Brand Names: Yervoy

Drug Type: Biotech

Chemical Formula: -

CAS Number: 477202-00-9

Unique Ingredient Identifier: 6T8C155666

Background: Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

Ipilimumab was granted FDA approval on 25 March 2011.

Indication: Ipilimumab is indicated in the following cancerous conditions:

Melanoma

Renal Cell Carcinoma (RCC)

Colorectal Cancer

Hepatocellular Carcinoma

Non-Small Cell Lung Cancer (NSCLC)

Malignant Pleural Mesothelioma

Esophageal Cancer

- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab

Associated Conditions: Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)

Associated Therapies: First Line Chemotherapy

Clinical Trials

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Ipilimumab
Biological: Vemurafenib

First Posted Date: 2012-08-28

Last Posted Date: 2018-07-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 70

Registration Number: NCT01673854

Locations: 🇺🇸
University Hospitals Of Cleveland, Cleveland, Ohio, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States

and more 11 locations

An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

Phase 1

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Biological: Nivolumab
Drug: Cabozantinib
Drug: Sorafenib
Drug: Ipilimumab

First Posted Date: 2012-08-07

Last Posted Date: 2024-11-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 659

Registration Number: NCT01658878

Locations: 🇺🇸
Local Institution - 0002, Ann Arbor, Michigan, United States
🇺🇸
Local Institution - 0008, Los Angeles, California, United States
🇺🇸
Local Institution - 0048, Washington, District of Columbia, United States

and more 57 locations

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

Phase 1

Completed

Conditions: Advanced Melanoma
Metastatic Melanoma

Interventions: Biological: Nivolumab
Drug: Ipilimumab

First Posted Date: 2012-06-18

Last Posted Date: 2024-04-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 170

Registration Number: NCT01621490

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇳🇱
Local Institution - 0016, Amsterdam, Netherlands
🇺🇸
University Of Chicago, Chicago, Illinois, United States

and more 11 locations

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

Phase 1

Terminated

Conditions: Melanoma

Interventions: Drug: Epacadostat
Drug: Placebo
Drug: ipilimumab

First Posted Date: 2012-05-24

Last Posted Date: 2019-03-26

Lead Sponsor: Incyte Corporation

Target Recruit Count: 136

Registration Number: NCT01604889

Doxycycline, Temozolomide and Ipilimumab in Melanoma

Phase 1

Terminated

Conditions: Melanoma

Interventions: Drug: Doxycycline
Drug: Ipilimumab
Drug: Temozolomide

First Posted Date: 2012-05-02

Last Posted Date: 2020-09-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 12

Registration Number: NCT01590082

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma

Phase 2

Conditions: Melanoma

Interventions: Drug: Ipilimumab
Radiation: Stereotactic Ablative Radiosurgery (SART)

First Posted Date: 2012-03-29

Last Posted Date: 2016-02-01

Lead Sponsor: Wolfram Samlowski

Target Recruit Count: 50

Registration Number: NCT01565837

Locations: 🇺🇸
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States

Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma

Phase 1

Terminated

Conditions: Malignant Melanoma

Interventions: Drug: Ipilimumab
Radiation: Radiotherapy

First Posted Date: 2012-03-19

Last Posted Date: 2016-06-09

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 19

Registration Number: NCT01557114

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇫🇷
Gustave Roussy Cancer Campus, Villejuif, Val de Marne, France

Ipilimumab and GMCSF Immunotherapy for Prostate Cancer

Phase 2

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: Ipilimumab
Drug: GM-CSF

First Posted Date: 2012-02-10

Last Posted Date: 2015-10-05

Lead Sponsor: Lawrence Fong

Registration Number: NCT01530984

Locations: 🇺🇸
University of California, San Francisco, California, United States

First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

Phase 2

Completed

Conditions: Urothelial Carcinoma

Interventions: Drug: Gemcitabine
Drug: Cisplatin
Drug: Ipilimumab

First Posted Date: 2012-02-02

Last Posted Date: 2022-07-11

Lead Sponsor: Hoosier Cancer Research Network

Target Recruit Count: 36

Registration Number: NCT01524991

Locations: 🇺🇸
IU Health Goshen Hospital, Goshen, Indiana, United States
🇺🇸
Tisch Cancer Institute at Mount Sinai Medical Center, New York, New York, United States
🇺🇸
City of Hope: Duarte, Duarte, California, United States

and more 5 locations

RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA

Phase 1

Completed

Conditions: Metastatic Melanoma

Interventions: Drug: Ipilimumab
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2011-12-23

Last Posted Date: 2021-08-10

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 22

Registration Number: NCT01497808

Locations: 🇺🇸
Abramson Cancer Center of the Universirty of Pennsylvania, Philadelphia, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy